Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Venook, A; Niedzwiecki, D; Hollis, D; Sutherland, S; Goldberg, R; Alberts, S; Benson, A; Wade, J; Schilsky, R; Mayer, R

Published Date

  • June 20, 2006

Published In

Volume / Issue

  • 24 / 18

Start / End Page

  • 148S - 148S

Published By

Pages

  • 1

International Standard Serial Number (ISSN)

  • 0732-183X

Conference Name

  • 42nd Annual Meeting of the American-Society-of-Clinical-Oncology

Conference Location

  • Atlanta, GA

Conference Start Date

  • June 2, 2006

Conference End Date

  • June 6, 2006